Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing treatments for degenerative retinal diseases, has scheduled a webcast for March 17, 2025, at 4:30 p.m. Eastern Time. The event will present the company's fourth quarter and full year 2024 financial results, along with a business update.
The webcast will be accessible through the company's investor relations website and will remain available for replay for approximately 90 days following the presentation.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti per le malattie degenerative della retina, ha programmato un webcast per il 17 marzo 2025, alle 16:30 ora orientale. L'evento presenterà i risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme a un aggiornamento aziendale.
Il webcast sarà accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda e rimarrà disponibile per la riproduzione per circa 90 giorni dopo la presentazione.
Belite Bio (NASDAQ: BLTE), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de tratamientos para enfermedades degenerativas de la retina, ha programado una transmisión web para el 17 de marzo de 2025, a las 4:30 p.m. hora del Este. El evento presentará los resultados financieros del cuarto trimestre y del año completo 2024, junto con una actualización comercial.
La transmisión web será accesible a través del sitio web de relaciones con inversores de la empresa y estará disponible para su repetición durante aproximadamente 90 días después de la presentación.
Belite Bio (NASDAQ: BLTE), 퇴행성 망막 질환 치료제 개발에 초점을 맞춘 임상 단계의 생명공학 회사가 2025년 3월 17일 동부 표준시 오후 4:30에 웹캐스트를 예정하고 있습니다. 이 이벤트에서는 2024년 4분기 및 연간 재무 결과와 함께 사업 업데이트가 발표될 것입니다.
웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접근할 수 있으며 발표 후 약 90일 동안 재생이 가능합니다.
Belite Bio (NASDAQ: BLTE), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de traitements pour les maladies dégénératives de la rétine, a programmé un webinaire pour le 17 mars 2025 à 16h30, heure de l'Est. L'événement présentera les résultats financiers du quatrième trimestre et de l'année complète 2024, ainsi qu'une mise à jour sur l'entreprise.
Le webinaire sera accessible via le site web des relations investisseurs de l'entreprise et restera disponible en replay pendant environ 90 jours après la présentation.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für degenerative Netzhauterkrankungen konzentriert, hat ein Webcast für den 17. März 2025 um 16:30 Uhr Eastern Time angesetzt. Die Veranstaltung wird die Finanzergebnisse des vierten Quartals und des gesamten Jahres 2024 sowie ein Unternehmensupdate präsentieren.
Der Webcast wird über die Investor-Relations-Website des Unternehmens zugänglich sein und für etwa 90 Tage nach der Präsentation für eine Wiederholung verfügbar bleiben.
- None.
- None.
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 17, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2024.
Webcast Information
Date: Monday, March 17, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/481614529
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When will Belite Bio (BLTE) report Q4 and full year 2024 earnings?
How can investors access Belite Bio's (BLTE) Q4 2024 earnings webcast?
How long will Belite Bio's (BLTE) Q4 2024 earnings webcast replay be available?
What will be discussed in Belite Bio's (BLTE) March 17 webcast?
